{"analyses":[{"ciLowerLimit":"-6.0093","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.6098","estimateComment":"A positive difference between the treatment groups favors the panitumumab group.","groupDescription":"Repeated measures mixed model includes treatment, geographic region, ECOG score, assessment week, and treatment by assessment week interaction as fixed effects, and subjects a random effect. An unstructured covariance matrix is used in the mixed model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"LS Mean Difference","paramValue":"-0.1998"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.1564","upperLimit":"6.8697","value":"1.3567"},{"groupId":"OG001","lowerLimit":"-4.4887","upperLimit":"6.8025","value":"1.1569"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"description":"The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from \"0\" to \"4\" representing \"Not at All\" through to \"Very Much True\". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).","dispersionType":"95% Confidence Interval","groups":[{"description":"Cetuximab 400 mg/m\\^2 as an initial dose, followed by 250 mg/m\\^2 intravenously (IV) every 7 days.","id":"OG000","title":"Cetuximab"},{"description":"Panitumumab 6 mg/kg IV every 14 days.","id":"OG001","title":"Panitumumab"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Patient reported outcomes (PRO) analysis set participants with available data.","reportingStatus":"POSTED","timeFrame":"From Study Day 1 through the last day of treatment or disease progression, up to Week 85.","title":"Change From Baseline in NCCN FCSI Functional Well-being Scale Score","type":"SECONDARY","unitOfMeasure":"scores on a scale"}